Cambridge Investment Research Advisors, Inc. Argenx Se Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Argenx Se stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 985 shares of ARGX stock, worth $611,655. This represents 0.0% of its overall portfolio holdings.
Number of Shares
985Holding current value
$611,655% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
444Shares Held
29.1MCall Options Held
390KPut Options Held
272K-
Price T Rowe Associates Inc Baltimore, MD5.52MShares$3.43 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.07MShares$1.91 Billion3.02% of portfolio
-
Janus Henderson Group PLC London, X02.31MShares$1.44 Billion0.76% of portfolio
-
Capital World Investors Los Angeles, CA1.79MShares$1.11 Billion0.17% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$769 Million11.1% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $34.4B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...